Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset (ID:20343)

 Full screen view
Filter results: >>>>
Cell Small Molecule Small Mol Concentration (uM) Primary Target Pathway Mean Normalized Growth Rate Inhibition Value Increased Fraction Dead
MDA-MB-468 Taxol
0.1
Chemo
Chemotherapy
 -0.5472 0.80695
PDXHCI002 Doxorubicin
1.0
Chemo
Chemotherapy
 -0.6545 0.80551
MDA-MB-361 Pictilisib
10.0
pan PI3K
PI3K/mTOR
 -0.9375 0.80430
BT-20 Dinaciclib
0.31623
pan CDK
Cell cycle
 -0.6706 0.80415
MDA-MB-134-VI Ceritinib
10.0
ALK
RTK
 -0.9992 0.80386
SUM159PT Ceritinib
10.0
ALK
RTK
 -0.3800 0.80163
MDA-MB-468 Topotecan
1.0
Topo I
Chemotherapy
 -0.6652 0.79819
Hs 578T Topotecan
10.0
Topo I
Chemotherapy
 -0.4488 0.79649
CAMA-1 Doxorubicin
3.1623
Chemo
Chemotherapy
 -0.6517 0.79195
MDA-MB-468 Topotecan
3.1623
Topo I
Chemotherapy
 -0.6577 0.79091
MDA-MB-468 Taxol
1.0
Chemo
Chemotherapy
 -0.5218 0.78956
BT-20 Dinaciclib
0.1
pan CDK
Cell cycle
 -0.6475 0.78890
MDA-MB-157 Dinaciclib
0.1
pan CDK
Cell cycle
 -0.8610 0.78558
Hs 578T Topotecan
3.1623
Topo I
Chemotherapy
 -0.4314 0.78405
MDA-MB-468 Cediranib
10.0
VEGFR/cKIT
RTK
 -0.7083 0.78385
MDA-MB-468 Taxol
0.31623
Chemo
Chemotherapy
 -0.5157 0.78107
HCC1419 Ceritinib
10.0
ALK
RTK
 -0.8670 0.78048
PDXHCI002 Abemaciclib
10.0
CDK4/6
Cell cycle
 -0.6767 0.78021
MDA-MB-157 Doxorubicin
3.1623
Chemo
Chemotherapy
 -0.7766 0.77243
CAMA-1 Ceritinib
10.0
ALK
RTK
 -0.6988 0.76730
SUM159PT Doxorubicin
3.1623
Chemo
Chemotherapy
 -0.2740 0.76625
MCF 10A Doxorubicin
3.1623
Chemo
Chemotherapy
 -0.3242 0.76439
MCF7 Ceritinib
10.0
ALK
RTK
 -0.6157 0.76213
SUM149PT Topotecan
10.0
Topo I
Chemotherapy
 -0.4596 0.76066
MDA-MB-468 Topotecan
0.31623
Topo I
Chemotherapy
 -0.6142 0.75922